Spermidine Supplement for Blood Fats and Weight in Overweight People With High Cholesterol
Tests spermidine against placebo in overweight or obese adults with hyperlipidemia.
Plain-language title generated from the registry record
Registry title: Assessment of the Effects and Safety of Spermidine Supplementation on Blood Lipids and Body Weight in Overweight or Obese Individuals With Hyperlipidemia
Key facts
- Where
- Shanghai, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 60 years old?
Source: NCT07662330, who can take part
Where in China
- Shanghai Tenth People's HospitalShanghai, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Shanghai 10th People's Hospital
- Trial code
- NCT07662330
- Record updated
- 23 June 2026
- Original description
Evaluate the effect of spermidine supplementation on lipid profile changes in individuals with overweight or obesity accompanied by hyperlipidemia. Analyze the impact of spermidine on metabolic parameters and assess the safety of spermidine supplementation, including liver and kidney function, gastrointestinal reactions, and other adverse effects.Read full original descriptionShow less
Assessment of the Effects and Safety of Spermidine Supplementation on Blood Lipids and Body Weight in Overweight or Obese Individuals With Hyperlipidemia: A Randomized, Double-Blind, Placebo-Controlled Trial
Evaluate the effect of spermidine supplementation on lipid profile changes in individuals with overweight or obesity accompanied by hyperlipidemia. Analyze the impact of spermidine on metabolic parameters and assess the safety of spermidine supplementation, including liver and kidney function, gastrointestinal reactions, and other adverse effects.
Inclusion: Males or females aged 18 to 65 years; BMI ≥ 24 kg/m², without severe chronic diseases; Not currently using glucose-lowering or lipid-lowering medications; Dyslipidemia defined as triglycerides ≥ 1.7 mmol/L or total cholesterol ≥ 5.2 mmol/L; No active weight loss or weight gain diet within the past 1 month; No special dietary pattern changes (e.g., ketogenic, vegan, high-protein, meal replacement, intermittent fasting) within the past 1 month; No use of supplements that may affect polyamine intake (e.g., germ, yeast, fermented extracts, nutritional powders) within the past 2-4 weeks; Willing and able to provide signed informed consent.
Exclusion: Concurrent participation in any other weight-loss therapy; Current use of hypoglycemic or lipid-lowering medications; Participation in any other clinical trial within one month prior to signing the informed consent form; Diagnosis of acute or severe gastrointestinal disease; Known allergy to cellulose or wheat; History of cancer; Any other condition deemed by the investigator as inappropriate for trial participation; Renal insufficiency, indicated by abnormal serum creatinine levels; Hepatic impairment, defined as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >3 × upper limit of normal (ULN), or total bilirubin (TBIL) >3 × ULN; Pregnancy, lactation, or planning a pregnancy during the trial period.